SciFi Futures
← Capabilities
Biotech & Medicine/Foundational science

Directed vascular morphogenesis

Making endothelial cells build a hierarchical, leak-free blood-vessel tree from artery down to capillary wherever an engineered tissue needs one.

State of the art

Sacrificial-ink printing and self-assembling microvascular networks sustain perfused tissue constructs for weeks in vitro; ARPA-H PRINT (2024-2026) names capillary-scale vasculature as the central unmet challenge.

What’s blocking it
  • Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
  • Engineered endothelium is thrombogenic, so perfused constructs clot
  • No method guides anastomosis of a construct's vasculature to host vessels at scale

Who’s working on it

  • Christopher ChenResearcher
    Boston University and Wyss Institute

    Co-leads the Wyss 3D Organ Engineering Initiative and built vascular-engraftment-on-chip models of how engineered vessels connect to host tissue; elected to the National Academy of Medicine in 2025

  • Jennifer LewisResearcher
    Harvard John A. Paulson School of Engineering and Applied Sciences

    Developed SWIFT and co-SWIFT sacrificial-ink printing, which write perfusable and cell-lined channels through dense cellular matrices

  • Up to 176.8 million dollars over five years across five teams, with capillary-scale vasculature named as the central unmet challenge

  • Wyss Institute 3D Organ Engineering InitiativeAcademic lab

    Where the printing and the endothelial biology are combined; its ReConstruct adipose programme is the nearest clinical translation of printed vasculature

  • Antonios MikosResearcher
    Rice University

    Part of the Wake Forest-led PRINT kidney team announced in 2026, supplying the biomaterials side of printing perfusable renal tissue

  • PrintBioStartup

    Industry partner in the federal kidney bioprinting programme, one of very few companies working on vascularised print fidelity rather than cell therapy

What to invest in

KindInvestmentScale
researchMorphogen and flow-cue programs that drive capillary self-assembly into printed scaffolds, with perfusion and permeability metrics$$ $10M – $100M
researchNon-thrombogenic engineered endothelium validated under physiologic flow for months$$ $10M – $100M

Sci-fi concepts in reach

Autodoc medical podindirectEngineered organ-donor animalsindirectResurrection of extinct speciesindirectWhole-body rejuvenation treatmentindirectOn-demand replacement organsgatingdirectAI cybrid (AI persona in a grown human body)indirectIndustrial ectogenesis (hatcheries)indirectNexus-6 androids (replicants)indirectCruciform resurrection parasiteindirectResleeving (transferring a mind into a new body)indirect

Sources